Article Figures & Data
Tables
- TABLE 1.
Variation in frequency of Candida guilliermondii by geographic regiona
Region Total no. of Candida species isolates Total no. (%) of C. guilliermondii isolates Asia-Pacific 17,183 190 (1.1) Europe 41,187 392 (1.0) Latin America 11,280 413 (3.7) North America 6,111 34 (0.6) Total 75,761 1,029 (1.4) ↵ a Data were obtained from the ARTEMIS DISK Global Antifungal Surveillance Program, 2001 to 2003. Isolates represent all incident isolates from all sites of infection.
- TABLE 2.
Geographic variation in susceptibility of Candida guilliermondii to fluconazole and voriconazole
Region Antifungal agent No. of isolates tested % of isolatesa S SDD R Asia-Pacific Fluconazole 190 77.4 14.7 7.9 Voriconazole 105 87.6 2.9 9.5 Europe Fluconazole 392 73.0 14.0 13.0 Voriconazole 220 92.8 3.6 3.6 Latin America Fluconazole 413 77.0 12.8 10.2 Voriconazole 274 91.6 4.0 4.4 North America Fluconazole 34 67.7 23.5 8.8 Voriconazole 34 88.2 8.8 3.0 Total Fluconazole 1,029 75.2 14.0 10.8 Voriconazole 633 91.2 3.9 4.9 ↵ a All isolates were tested by the disk diffusion method performed in accordance with CLSI standard M44-A. S, susceptible, with zone diameters of ≥19 mm for fluconazole and ≥17 mm for voriconazole; SDD, susceptible-dose dependent, with zone diameters of 15 to 18 mm for fluconazole and 14 to 16 mm for voriconazole; R, resistant, with zone diameters of ≤14 mm for fluconazole and ≤13 mm for voriconazole.
- TABLE 3.
Susceptibility of Candida guilliermondii to fluconazole and voriconazole by clinical service
Clinical service (total no. of isolates)a Antifungal agent No. of isolates tested (%)b % of isolates from servicec % of isolates S SDD R Hematology-oncology (4,635) Fluconazole 47 (4.6) 1.0 78.7 6.4 14.9 Voriconazole 32 (5.1) 96.9 3.1 Medical (17,408) Fluconazole 159 (15.4) 0.9 79.9 13.2 6.9 Voriconazole 124 (19.6) 93.5 3.2 3.2 Surgical (5,126) Fluconazole 51 (5.0) 0.9 68.6 23.5 7.8 Voriconazole 47 (7.4) 91.5 4.3 4.3 Intensive care unit (10,052) Fluconazole 67 (6.5) 0.7 79.1 11.9 9.0 Voriconazole 55 (8.7) 90.9 1.8 7.3 Dermatology (1,457) Fluconazole 158 (15.3) 10.8 57.6 24.1 18.4 Voriconazole 121 (19.1) 90.9 6.6 2.5 Urology (649) Fluconazole 14 (1.4) 2.2 78.6 7.1 14.3 Voriconazole 6 (0.9) 83.3 16.7 Outpatient (6,414) Fluconazole 47 (4.6) 0.7 74.5 10.6 14.9 Voriconazole 25 (3.9) 84.0 8.0 8.0 Other, NOS (30,020) Fluconazole 486 (47.2) 1.6 79.2 11.5 9.3 Voriconazole 223 (35.2) 90.1 3.2 6.7 - TABLE 4.
Susceptibility of Candida guilliermondii to fluconazole and voriconazole by specimen type
Specimen type/site (total no. of isolates)a Antifungal agent No. of isolates tested (%)b % of isolates from sitec % of isolates S SDD R Blood (8,256) Fluconazole 307 (29.8) 3.7 85.0 9.1 5.9 Voriconazole 198 (31.3) 93.4 1.5 5.1 NSBF (3,155) Fluconazole 36 (3.5) 1.1 72.2 22.2 5.6 Voriconazole 30 (4.7) 96.7 3.3 Urine (9,722) Fluconazole 78 (7.6) 0.8 71.8 12.8 15.4 Voriconazole 51 (8.1) 80.4 3.9 15.7 Respiratory (20,274) Fluconazole 136 (13.2) 0.7 77.2 10.3 12.5 Voriconazole 72 (11.3) 88.8 4.2 7.0 Skin/soft tissue (4,986) Fluconazole 127 (12.3) 2.5 67.7 24.4 7.9 Voriconazole 103 (16.3) 93.4 5.8 1.0 Genital (15,831) Fluconazole 44 (4.3) 0.3 84.1 6.8 9.1 Voriconazole 20 (3.2) 95.0 5.0 Misc., NOS (13,537) Fluconazole 301 (29.3) 2.2 67.4 16.6 16.0 Voriconazole 159 (25.1) 89.9 5.7 4.4